检索结果-南通市图书馆

工程教育认证背景下RFID课程教学模式的改革研究

在线全文

学校读者我要写书评

暂无评论

湖北工程学院学报 2024年第3期44卷 95-99页

作者：王维虎刘艳超蒋超熊伟湖北工程学院计算机与信息科学学院湖北孝感432000 湖北工程学院生命科学技术学院湖北孝感432000

旨在探讨在工程教育专业认证背景下,物联网专业课程“RFID原理与应用”教学模式的改革。首先对工程教育专业认证背景和意义进行了介绍,然后分析了当前RFID课程教学模式存在的问题,并提出了课程的改革方法;再采用定量分析和定性分析方法... 详细信息

旨在探讨在工程教育专业认证背景下,物联网专业课程“RFID原理与应用”教学模式的改革。首先对工程教育专业认证背景和意义进行了介绍,然后分析了当前RFID课程教学模式存在的问题,并提出了课程的改革方法;再采用定量分析和定性分析方法对改革效果进行研究,证明了课程改革的有效性和课程特色;最后对教学改革过程中存在的问题进行分析,并提出改进建议。

关键词：工程教育认证 RFID 教学模式

维普期刊数据库博看期刊

Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis in 55 patients

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2017年第5期29卷 438-446页

作者： Ge Wen weihu wang Yujing Zhang Shaoqing Niu Qiwen Li Yexiong Li Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) Department of Radiation Oncology Peking University Cancer Hospital & Institute Department of Radiation Oncology the Third Affiliated Hospital of Guangzhou Medical University Department of Radiation Oncology Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Department of Radiation Oncology the First Affiliated Hospital of Sun Yat-sen University Department of Radiation Oncology National Cancer Center/Cancer Hospital Chinese Academy of Medical Science & Peking Union Medical College

Objective： To investigate potential prognostic factors affecting patient outcomes and to evaluate the optimal methods and effects of radiotherapy（RT） in the management of extramedullary plasmacytoma（EMP）.Methods： Data from 55 patients with EMP between November 1999 and August 2015 were collected. The median age was 51（range, 22–77） years. The median tumor size was 3.5（range, 1.0–15.0） cm. The median applied dose was 50.0（range, 30.0–70.0） Gy. Thirty-nine patients（70.9%） presented with disease in the head or neck region. Twelve patients received RT alone, 9 received surgery（S） alone, 3 received chemotherapy（CT） alone, and 3 patients did not receive any treatment. Combination therapies were applied in 28 ***：The median follow-up duration was 56 *** 5-year local recurrence-free survival（LRFS）,multiple myeloma-free survival（MMFS）,progression-free survival（PFS）and overall survival（OS）rates were 79.8%,78.6%,65.2% and 76.0%,*** analysis revealed that RT was a favourable factor for all examined ***,head and neck EMPs were associated with superior LRFS,MMFS and *** size〈4 cm was associated with superior MMFS,PFS and OS;serum M protein negativity was associated with superior MMFS and PFS;age≥50 years and local recurrence were associated with poor *** dose≥45 Gy group exhibited superior 5-year LRFS,MMFS and PFS rates（94.7%,94.4%,90.0%,respectively）,while the corresponding values for the dose〈45 Gy group were 62.5%（P=0.008）,53.3%（P=0.036）and 41.7%（P〈0.001）.Conclusions：Involved-site RT of at least 45 Gy should be considered for ***,patients with head and neck EMP,tumor size〈4 cm,age〈50 years and serum M protein negativity had better outcomes.

关键词： Extramedullary plasmacytoma prognostic factors radiotherapy multiple myeloma

Predictors of pathologic complete response in patients with residual flat mucosal lesions after neoadjuvant chemoradiotherapy for locally advanced rectal cancer

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2022年第4期34卷 383-394页

作者： Changlong Li Zhen Guan Yi Zhao Tingting Sun Zhongwu Li weihu wang Zhexuan Li Lin wang Aiwen Wu Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Gastrointestinal Cancer CenterPeking University Cancer Hospital&InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of RadiologyPeking University Cancer Hospital&InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of PathologyPeking University Cancer Hospital&InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of Radiation OncologyPeking University Cancer Hospital&InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of Cancer EpidemiologyPeking University Cancer Hospital&InstituteBeijing 100142China

Objective:The accurate prediction of tumor response to neoadjuvant chemoradiotherapy(nCRT)remains *** studies have investigated pathologic complete response(ypCR)prediction in patients with residual flat mucosal lesions after *** study aimed to identify variables for predicting ypCR in patients with residual flat mucosal lesions after nCRT for locally advanced rectal cancer(LARC).Methods:Data of patients with residual flat mucosal lesions after nCRT who underwent radical resection between 2009 and 2015 were retrospectively collected from the LARC database at Peking University Cancer *** and multivariate analyses of the association between clinicopathological factors and ypCR were performed,and a nomogram was constructed by incorporating the significant ***:Of the 246 patients with residual flat mucosal lesions included in the final analysis,56(22.8%)had *** and multivariate analyses showed that pretreatment cT stage(pre-cT)≤T2(P=0.016),magnetic resonance tumor regression grade(MR-TRG)1-3(P=0.001)and residual mucosal lesion depth=0 mm(P<0.001)were associated with a higher rate of ypCR.A nomogram was developed with a concordance index(C-index)of0.759 and the calibration curve showed that the nomogram model had good predictive *** follow-up time ranged from 3.0 to 113.3 months,with a median follow-up time of 63.77 *** multivariate Cox regression model showed that the four variables in the nomogram model were not risk factors for disease-free survival(DFS)or overall survival(OS).Conclusions:Completely flat mucosa,early cT stage and good MR-TRG were predictive factors for ypCR instead of DFS or OS in patients with LARC with residual flat mucosal lesions after *** mucosal re-evaluation before surgery is important,as it may contribute to decision-making and facilitate nonoperative management or organ preservation.

关键词： Rectal cancer preoperative chemoradiotherapy tumor regression grade flat mucosal lesions pathologic complete response

直肠癌患者新辅助治疗后临床完全缓解或近临床完全缓解行等待观察策略的远期预后:一项来自中国等待观察数据协作组的多中心登记研究

在线全文

学校读者我要写书评

暂无评论

中华胃肠外科杂志 2024年第4期27卷 372-382页

作者：赵一鸣王维虎张卫王林李帅王靖雯廖乐恩于冠宇孙振屈艳丽巩阳卢云武涛李云峰王权赵国华肖毅丁培荣章真武爱文北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤中心三病区恶性肿瘤发病机制及转化研究教育部重点实验室北京100142 北京大学肿瘤医院暨北京市肿瘤防治研究所放射治疗科恶性肿瘤发病机制及转化研究教育部重点实验室北京100142 海军军医大学附属长海医院肛肠外科上海200433 复旦大学上海医学院附属肿瘤医院放射肿瘤科复旦大学上海医学院肿瘤学系上海市放射肿瘤学重点实验室上海200032 中山大学肿瘤防治中心结直肠外科广州510060 中国医学科学院北京协和医学院北京协和医院基本外科北京100730 辽宁省肿瘤医院普通外科沈阳110042 吉林大学第一医院胃结直肠外科长春130021 青岛大学附属医院普外科青岛266555 云南省肿瘤医院结直肠外科昆明650118 消化系肿瘤整合防治全国重点实验室恶性肿瘤转化研究北京市重点实验室北京100142

目的报告中国直肠癌患者新辅助治疗后等待观察后的远期结局。方法基于真实世界的多中心横断面研究。纳入新辅助治疗后评价为临床完全缓解(cCR)或近cCR(near-cCR)进行等待观察的直肠癌患者以及少数新辅助治疗后疗效较好、以活检为目的行... 详细信息

目的报告中国直肠癌患者新辅助治疗后等待观察后的远期结局。方法基于真实世界的多中心横断面研究。纳入新辅助治疗后评价为临床完全缓解(cCR)或近cCR(near-cCR)进行等待观察的直肠癌患者以及少数新辅助治疗后疗效较好、以活检为目的行局部切除确认ypCR的患者,随访时间需≥2年;剔除基线时伴有远处转移或带瘤生存自行等待观察的患者。根据以上标准,回顾性收集中国等待观察数据协作组(CWWD)中的数据信息,包括基本信息、新辅助治疗类型、治疗前影像学检查结果、新辅助治疗后疗效评价、补救措施及治疗结局等,分析本组患者新辅助治疗后等待观察后的远期结局,并比较cCR及near-cCR两组间的差异。结果来自8家医疗中心(北京大学肿瘤医院、复旦大学附属肿瘤医院、中山大学附属肿瘤医院、上海长海医院、北京协和医院、辽宁省肿瘤医院、吉林大学附属第一医院以及云南省肿瘤医院)共计318例接受等待观察且随访超过两年的直肠癌患者的临床资料。全组患者中男性221例(69.4%),女性107例(30.6%);中位年龄60(26~86)岁。肿瘤距离肛缘中位距离为3.4(0~10.4)cm。291例接受新辅助治疗后评效为cCR,27例评效为near-cCR。中位随访48.4(10.2~110.3)个月,5年累计总体生存率(OS)为92.4%(95%CI:86.8%~95.7%),5年累计疾病特异生存率(CSS)为96.6%(95%CI:92.2%~98.5%),5年累计器官保留研究校正无病生存率(OP-DFS)为86.6%(95%CI:81.0%~90.7%),5年累计器官保留率(OPR)为85.3%(95%CI:80.3%~89.1%),5年局部再生率为18.5%(95%CI:14.9%~20.8%),5年远处转移率为8.2%(95%CI:5.4%~12.5%)。全组共56例发生局部再生,82.1%(46/56)的局部再生发生于2年内,91.1%(51/56)的局部再生发生于3年内,中位再生时间为11.7(2.5~66.6)个月。91.1%(51/56)的局部再生发生于肠腔内。共23例患者发生远处转移,60.9%(14/23)远处转移发生于2年内,73.9%(17/23)发生于3年内,中位远处转移时间为21.9(2.6~90.3)个月。17例发生于单个脏器,6例为多脏器转移;累及脏器包括肺转移(15例,65.2%)、肝转移(6例,26.1%)和骨转移(7例,30.4%)。cCR和near-cCR患者的OS、CSS、OP-DFS及远处转移率差异均无统计学意义(均P>0.05);但相比cCR患者,near-cCR患者5年局部再生率较高(41.6%比16.4%,P<0.01),5年OPR率较低(69.2%比88.0%,P<0.001)。局部再生和远处转移拯救成功率(行拯救性手术后转为无疾病证据状态)分别为82.1%(46/56)和13.0%(3/23)。结论新辅助治疗后达到cCR或near-cCR接受等待观察的直肠癌患者具有良好的肿瘤学结局和较高的器官保留率。等待观察过程中的局部再生和远处转移具有一定规律,局部再生拯救率较高,开展过程中需要强调密切的随访和及时的补救。

关键词：直肠肿瘤新辅助治疗等待观察器官保留

安徽省不同生态环境下夏大豆新品种产量与农艺性状间的关系

在线全文

学校读者我要写书评

暂无评论

中国种业 2024年第6期 100-108页

作者：胡国玉杨勇王雅楠李杰坤王大刚吴倩王维虎黄志平安徽省农业科学院作物研究所合肥230031

为明确安徽省新育成大豆品种在不同生态环境下的产量及主要农艺性状表现,分析了2016-2021年安徽省夏大豆新品种比较试验的相关数据。结果表明:不同年份新品种比对照平均增减产-1.57%~4.10%,新品种的平均单株荚数比对照增加11.83%~23.45%... 详细信息

为明确安徽省新育成大豆品种在不同生态环境下的产量及主要农艺性状表现,分析了2016-2021年安徽省夏大豆新品种比较试验的相关数据。结果表明:不同年份新品种比对照平均增减产-1.57%~4.10%,新品种的平均单株荚数比对照增加11.83%~23.45%,百粒重降低5.78%~10.94%,2021年新品种的平均每荚粒数比对照增加3.03%;新品种产量与单株荚数、每荚粒数及百粒重呈显著或极显著正相关的试验点次分别占总试验点次的67.74%、32.26%和16.13%,新品种产量与营养生长期天数、主茎节数及有效分枝数呈显著或极显著正相关的试验点次分别占总试验点次的38.71%、41.94%和38.71%;有5年高产新品种的单株荚数和有效分枝数显著或极显著大于普通新品种,有4年高产新品种的营养生长期天数、主茎节数显著或极显著大于普通新品种;安徽省大豆新品种产量的提高主要得益于单株荚数和每荚粒数的增加。因此,在安徽省生态环境下,增加大豆品种的单株荚数和每荚粒数,适当延长品种营养生长期,增加主茎节数和有效分枝数均有利于提高品种产量。

关键词：安徽大豆新品种产量农艺性状相关性

维普期刊数据库博看期刊

Adjuvant radiotherapy in central hepatocellular carcinoma after narrow-margin hepatectomy:A 10-year real-world evidence

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2020年第5期32卷 645-653页

作者： Weiqi Rong Weibo Yu Liming wang Fan Wu Kai Zhang Bo Chen Chengli Miao Liguo Liu Songlin An Changcheng Tao weihu wang Jianxiong Wu Department of Hepatobiliary Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Pathology and Laboratory Medicine David Geffen School of MedicineUniversity of California Los AngelesLos AngelesCA 90095USA Department of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Retroperitoneal Tumor Surgery Peking University International HospitalBeijing 102206China Department of General Surgery China-Japan Friendship HospitalBeijing 100029China Department of Peritoneal Cancer Surgery Beijing Shijitan HospitalCapital Medical University BeijingBeijing 100038China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of Radiation OncologyPeking University Cancer Hospital&InstituteBeijing 100142China

Objective:A prospective randomized control study investigated the feasibility and efficacy of adjuvant radiotherapy on patients with central hepatocellular carcinoma(HCC)after narrow-margin hepatectomy(<1 cm).This study presents an updated 10-year real-world evidence to further characterize the role of adjuvant ***:Patients with central HCC after narrow-margin hepatectomy(<1 cm)were prospectively assigned to adjuvant radiotherapy group and control ***'outcome,adverse events,long-term recurrence and survival rates were ***:The 1-,5-,and 10-year recurrence-free survival(RFS)rates were 81.0%,43.9%,and 38.7%,respectively in adjuvant radiotherapy group and 71.7%,35.8%,and 24.2%,respectively in control group(log-rank test,P=0.09).The 1-,5-,and 10-year overall survival(OS)rates were 96.6%,54.7%,and 42.8%,respectively in adjuvant radiotherapy group and 90.2%,55.1%,and 30.0%,respectively in control group(log-rank test,P=0.20).The 1-,5-,and 10-year RFS rates for patients with small HCC(≤5 cm)were 91.1%,51.6%,and 48.4%,respectively in adjuvant radiotherapy group and 80.0%,36.6%,and 26.6%,respectively in control group(log-rank test,P=0.03).Landmark analysis demonstrated that patients with small HCC in adjuvant radiotherapy group had a significantly improved OS in second five years after treatment in comparison to patients in control group(log-rank test,P=0.05).Conclusions:Our updated results showed a sustained clinical benefit on reducing recurrence,improving longterm survival for small central HCC by adjuvant radiotherapy after narrow-margin ***-term survival data also indicated that hepatectomy is an optimal treatment for selected patients with central HCC.

关键词： Three-dimensional conformal radiotherapy recurrence long-term survival narrow-margin hepatectomy real-world evidence

Genetic polymorphisms in genes regulating cell death and prognosis of patients with rectal cancer receiving postoperative chemoradiotherapy

在线全文

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2023年第4期20卷 297-316页

作者： Hongxia Chen Luxi Yin Jie Yang Ningxin Ren Jinna Chen Qixuan Lu Ying Huang Yanru Feng weihu wang Shulian wang Yueping Liu Yongwen Song Yexiong Li Jing Jin Wen Tan Dongxin Lin State Key Laboratory of Molecular Oncology Department of Etiology and CarcinogenesisBeijing Key Laboratory for Carcinogenesis and Cancer PreventionNational Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South ChinaGuangzhou 510060China

Objective:The identification of biomarkers for predicting chemoradiotherapy efficacy is essential to optimize personalized *** study determined the effects of genetic variations in genes involved in apoptosis,pyroptosis,and ferroptosis on the prognosis of patients with locally advanced rectal cancer receiving postoperative chemoradiotherapy(CRT).Methods:The Sequenom MassARRAY was used to detect 217 genetic variations in 40 genes from 300 patients with rectal cancer who received postoperative *** associations between genetic variations and overall survival(OS)were evaluated using hazard ratios(HRs)and 95%confidence intervals(CIs)computed using a Cox proportional regression *** experiments were performed to determine the functions of the arachidonate 5-lipoxygenase(ALOX5)gene and the ALOX5 rs702365 ***:We detected 16 genetic polymorphisms in CASP3,CASP7,TRAILR2,GSDME,CASP4,HO-1,ALOX5,GPX4,and NRF2 that were significantly associated with OS in the additive model(P[C]represses ALOX5 transcription and corollary experiments suggested that ALOX5 may promote colon cancer cell growth by mediating an inflammatory ***:Polymorphisms in genes regulating cell death may play essential roles in the prognosis of patients with rectal cancer who are treated with postoperative CRT and may serve as potential genetic biomarkers for individualized treatment.

关键词： Rectal neoplasms genetic variation regulated cell death overall survival ALOX5

Long-term follow-up of volumetric modulated arc therapy in definitive radiotherapy for cervical cancer: A single-center retrospective experience

在线全文

学校读者我要写书评

暂无评论

Radiation Medicine and Protection 2020年第2期1卷 81-87页

作者： Yidi Yuan Jing You weihu wang Xiaofan Li Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of Radiation Oncology Peking University Cancer Hospital and InstituteBeijingChina

Objective:To evaluate the treatment outcomes and toxicity of volumetric modulated arc therapy(VMAT)in definitive radiotherapy for patients with cervical ***:Medical records of 440 patients with cervical cancer treated with VMAT in definitive radiotherapy with or without concurrent chemotherapy between January 2010 and June 2015 in our institution were retrospectively reviewed.A dose of 45 Gy was prescribed to the planning target volume with VMAT in 25 fractions,followed by high-dose rate intracavitary brachytherapy with 28–36 Gy in 4–6 *** time was estimated using Kaplan-Meier *** factors for treatment failure were identified using Cox proportional hazards regression ***:The median follow-up periods were 58.3 months(range:2.7–112.9 months).The 3-and 5-year survival rates were overall survival(OS)79.4%and 74.4%,cancer-specific survival(CSS)81.4%and 77.1%,progressionfree survival(PFS)73.3%and 71.1%,locoregional control(LC)83.3%and 82%and distant metastasis-free survival(DMFS)80.8%and 77.7%,*** 5-year OS for patients with different stages was IB191.6%,IB2100%,IIA 82.5%,IIB 74.4%,IIIA 57.1%,IIIB 61.7%and IVB 17.6%,*** the 124 patients with recurrence,93 patients(75.0%)experienced distant *** analysis showed that non-squamous cell carcinoma of the cervix(P<0.001),more advanced stage(P=0.004),pelvic lymph node metastasis(P<0.001)and para-aortic lymph node metastasis(P=0.019)were all independent risk factors of *** incidence of grades 3–4 late bowel toxicities was 2.7%.No grades 3–4 bladder toxicity was ***:This study demonstrated that the use of VMAT in definitive radiotherapy resulted in satisfactory outcomes with acceptable toxicities for patients with cervical *** metastasis predominated as the pattern of disease *** studies are needed to investigate the intensified systemic therapies.

关键词： Volumetric modulated arc therapy Cervical cancer Definitive radiotherapy

Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2015年第5期27卷 516-523页

作者： Bo Jia Yuankai Shi Suyi Kang Sheng Yang Shaoxuan Hu Yexiong Li Mei Dong weihu wang Jianliang Yang Liqiang Zhou Peng Liu Shengyu Zhou Yan Qin Lin Gui Changgong Zhang Hua Lin Shanshan Chen Lin wang Xiaohui He Department of Medical Oncology Cancer HospitalChinese Academy of Medical Sciences & Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Department of Radiation Oncology Cancer HospitalChinese Academy of Medical Sciences & Peking Union Medical College Department of Medical Record Library Cancer HospitalChinese Academy of Medical Sciences & Peking Union Medical College

Background： The role of rituximab in combination with CHOP regimen in patients with stage I diffuse large B-cell lymphoma （DLBCL） remains to be defined. We aimed to compare CHOP plus rituximab （R-CHOP） with CHOP alone and determine the value of radiotherapy in these patients. Methods： Between 2003 and 2009, 140 untreated patients with stage I DLBCL were retrospectively analyzed in this study. Results： Seventy-eight patients were treated in R-CHOP group and 62 in CHOP group. Ninety-one patients received additional radiotherapy at the end of chemotherapy. The different treatment groups were well-balanced with respect to baseline characteristics. Complete response （CR） rate was 77% both in R-CHOP and CHOP groups （P=0.945）. After a median follow-up period of 56 months, patients received R-CHOP regimen had similar 5-year progression-free survival （PFS）（76% vs. 85%; log-rank P=0.215） and 5-year overall survival （OS）（90% vs. 96%; log-rank P=0.175） compared with those with CHOP alone. Patients with radiotherapy had significantly increased 5-year PFS compared with those who had chemotherapy alone （86% vs. 71%; log-rank P=0.005）. At multivariate analysis, patients who had CR （P=0.008） and received radiotherapy （P=0.003） were significantly associated with superior PFS. Conclusions： CHOP alone could be as effective as R-CHOP regimen and additional radiotherapy would be necessary for stage I or stage I non-bulky DLBCL patients.

关键词： Diffuse large B-cell lymphoma (DLBCL) stage I R-CHOP radiotherapy prognosis